Table 33.
Examples of caspases inhibitors with various P4 substituents designed using tethering technology.296
![]() |
enzyme assays IC50, μM | cellular assays IC50, μM | ||||
---|---|---|---|---|---|---|
rh-Casp-1 | rh-Casp-3 | rh-Casp-7 | rh-Casp-8 | NT2 | ||
![]() |
350 | 0.90 | 0.080 | > 10.0 | 9.10 | 15.30 |
![]() |
351 | 0.087 | 0.14 | 3.28 | 8.22 | 30.0 |
![]() |
352 | 0.065 | 0.036 | 0.81 | 2.09 | 4.56 |
![]() |
353 | 0.92 | 0.071 | 9.73 | 7.65 | > 10.0 |
![]() |
354 | 1.93 | 0.018 | 9.71 | > 10.0 | 5.74 |
![]() |
355 | 0.13 | 0.026 | 1.13 | 1.75 | 3.08 |
![]() |
356 | 0.19 | 0.012 | 0.49 | 6.59 | 3.42 |
![]() |
357 | 0.22 | 0.0079 | 0.73 | 2.46 | 1.39 |